Search Result

Results for "

DOPA

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (6) Adenosine Receptor (1) Adrenergic Receptor (4) Biochemical Assay Reagents (2) Carboxypeptidase (1) COMT (2) DNA/RNA Synthesis (1) Dopamine Receptor (24) Dopamine Transporter (1) Drug Intermediate (1) Drug Metabolite (2) Endogenous Metabolite (18) GABA Receptor (3) Glycosidase (1) Imidazoline Receptor (4) Isotope-Labeled Compounds (7) mGluR (1) Monoamine Oxidase (6) nAChR (3) Opioid Receptor (5) Reactive Oxygen Species (1) Serotonin Transporter (1) Tyrosinase (5)
By Research Areas:	Cancer (8) Endocrinology (1) Inflammation/Immunology (5) Metabolic Disease (2) Neurological Disease (42)

By Targets:

5-HT Receptor (6)

Adenosine Receptor (1)

Adrenergic Receptor (4)

Biochemical Assay Reagents (2)

Carboxypeptidase (1)

COMT (2)

DNA/RNA Synthesis (1)

Dopamine Receptor (24)

Dopamine Transporter (1)

Drug Intermediate (1)

Drug Metabolite (2)

Endogenous Metabolite (18)

GABA Receptor (3)

Glycosidase (1)

Imidazoline Receptor (4)

Isotope-Labeled Compounds (7)

mGluR (1)

Monoamine Oxidase (6)

nAChR (3)

Opioid Receptor (5)

Reactive Oxygen Species (1)

Serotonin Transporter (1)

Tyrosinase (5)

By Research Areas:

Cancer (8)

Endocrinology (1)

Inflammation/Immunology (5)

Metabolic Disease (2)

Neurological Disease (42)

Inhibitors & Agonists

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N0304S2

*L-DOPA-13C* 1 Publications Verification	Dopamine Receptor Endogenous Metabolite	Neurological Disease
L-DOPA- ¹³C is the ¹³C labeled L-DOPA[1]. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease[2][3][4].

HY-113404

DL-Dopa	Endogenous Metabolite	Others
DL-Dopa is a beta-hydroxylated derivative of phenylalanine.

HY-110286

6-Hydroxy-DOPA	DNA/RNA Synthesis	Cancer
6-Hydroxy-DOPA is a selective and effective allosteric inhibitor of the RAD52 ssDNA binding domain. 6-Hydroxy-DOPA can be used for the research of cancer .

HY-132404S

*(rac)-3-O-Methyl DOPA-d3*	Isotope-Labeled Compounds	Others
(rac)-3-O-Methyl DOPA-d₃ is the deuterium labeled (rac)-3-O-Methyl DOPA[1].

HY-132392S

*L-DOPA-2,5,6-d3*	Dopamine Receptor Endogenous Metabolite	Neurological Disease
L-DOPA-2,5,6-d₃ is the deuterium labeled L-DOPA. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain[1][2][3].

HY-N0304

L-DOPA Maximum Cited Publications 20 Publications Verification LevoDOPA; 3,4-Dihydroxyphenylalanine	Dopamine Receptor Endogenous Metabolite	Neurological Disease Cancer
L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .

HY-113404S

*DL-Dopa-d6*	Isotope-Labeled Compounds Endogenous Metabolite	Others
DL-Dopa-d₆ is the deuterium labeled DL-Dopa. DL-Dopa is a beta-hydroxylated derivative of phenylalanine.

HY-113404S1

*L-Dopa-d3*	Endogenous Metabolite Isotope-Labeled Compounds	Others
L-Dopa-d₃ is deuterated labeled DL-Dopa (HY-113404). DL-Dopa is a beta-hydroxylated derivative of phenylalanine.

HY-121939R

*6-Hydroxy-L-DOPA* (Standard)**	Biochemical Assay Reagents	Others
6-Hydroxy-L-DOPA (Standard) is the analytical standard of 6-Hydroxy-L-DOPA. This product is intended for research and analytical applications. 6-Hydroxy-L-DOPA is a nucleic acid functionalized with electron-donating units .

HY-N0304A

*L-DOPA* sodium** LevoDOPA sodium; 3,4-Dihydroxyphenylalanine sodium	Dopamine Receptor Endogenous Metabolite	Neurological Disease
L-DOPA (Levodopa) sodium is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA sodium can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA sodium has anti-allodynic effects, and can be used for Parkinson's disease research .

HY-N0304R

*L-DOPA* (Standard)** LevoDOPA (Standard); 3,4-Dihydroxyphenylalanine (Standard)	Dopamine Receptor Endogenous Metabolite	Neurological Disease Cancer
L-DOPA (Standard) is the analytical standard of L-DOPA. This product is intended for research and analytical applications. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .

HY-121939

6-Hydroxy-L-DOPA	Biochemical Assay Reagents	Others
6-Hydroxy-L-DOPA is a nucleic acid functionalized with electron-donating units .

HY-141647

*[18F]-Labeled L-dopa* precursor**	Dopamine Receptor	Others
[18F]-Labeled L-dopa precursor is a precursor for synthesis of 18F-labeled L-dopa extracted from patent WO2014095739A1, example 8 .

HY-Y0351

Phenylthiourea Phenylthiocarbamide	Others	Others
Phenylthiourea (Phenylthiocarbamide) is an inhibitor of phenoloxidase. Phenylthiourea inhibits enzymatic oxidation of DOPA by phenoloxidase (K_i: 0.21 μM) .

HY-W096171

D-Dopa 3-Hydroxy-D-tyrosine	Carboxypeptidase	Neurological Disease
D-Dopa is a non-competitive, allosteric inhibitor for glutamate carboxypeptidase II (GCPII) with an IC₅₀ of 200 nM. D-Dopa exhibits good pharmacokinetic characteristics, and low blood-brain barrier permeability in mouse model .

HY-113468R

*3-O-Methyl-DL-DOPA* (Standard)**	Endogenous Metabolite	Neurological Disease
3-O-Methyl-DL-DOPA (Standard) is the analytical standard of 3-O-Methyl-DL-DOPA. This product is intended for research and analytical applications. 3-O-Methyl-DL-DOPA is an endogenous metabolite present in Cerebrospinal_Fluid that can be used for the research of Epilepsy, Purine Nucleoside Phosphorylase Deficiency and Aromatic L Amino Acid Decarboxylase Deficiency [4].

HY-N0304S

*L-DOPA-d6* LevoDOPA-d₆; 3,4-Dihydroxyphenylalanine-d₆	Dopamine Receptor Endogenous Metabolite	Neurological Disease
L-DOPA-d₆ is the deuterium labeled L-DOPA. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease[1][2][3].

HY-113468A

3-O-Methyldopa 1 Publications Verification 3-Methoxy-L-tyrosine; 3-O-Methyl-L-DOPA	Dopamine Receptor Endogenous Metabolite	Neurological Disease
3-O-Methyldopa (3-Methoxy-L-tyrosine) is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of l-DOPA and dopamine .

HY-N0304S1

*L-DOPA-13C6* LevoDOPA-¹³C₆; 3,4-Dihydroxyphenylalanine-¹³C₆	Dopamine Receptor Endogenous Metabolite	Neurological Disease
L-DOPA- ¹³C₆ is the ¹³C-labled L-DOPA . L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .

HY-33549

α-Methyl-p-tyrosine	Others	Neurological Disease Cancer
α-Methyl-p-tyrosine is a competitive inhibitor of tyrosine hydroxylase, which converts tyrosine into DOPA. α-Methyl-p-tyrosine is also an orally active inhibitor of catecholamine synthesis, inhibiting the hydroxylation of tyrosine into DOPA. α-Methyl-p-tyrosine can be used in research related to epilepsy, glaucoma, cancer, and other related diseases .

HY-113468

3-O-Methyl-DL-DOPA 3-Methoxytyrosine	Endogenous Metabolite	Neurological Disease
3-O-Methyl-DL-DOPA is an endogenous metabolite present in Cerebrospinal_Fluid that can be used for the research of Epilepsy, Purine Nucleoside Phosphorylase Deficiency and Aromatic L Amino Acid Decarboxylase Deficiency .

HY-116016

Etilevodopa L-DOPA ethyl ester; LevoDOPA ethyl ester	Dopamine Receptor Drug Metabolite	Neurological Disease
Etilevodopa (L-Dopa ethyl ester), an ethyl-ester proagent of Levodopa, is rapidly hydrolyzed to Levodopa and ethanol by nonspecific esterases in the gastrointestinal tract. Etilevodopa is used for the treatment of Parkinson disease (PD). Levodopa is the direct precursor of dopamine and is a suitable proagent as it facilitates CNS penetration and delivers dopamine .

HY-116016A

Etilevodopa hydrochloride L-DOPA ethyl ester hydrochloride; LevoDOPA ethyl ester hydrochloride	Dopamine Receptor Drug Metabolite	Neurological Disease
Etilevodopa (L-Dopa ethyl ester) hydrochloride, an ethyl-ester proagent of Levodopa, is rapidly hydrolyzed to Levodopa and ethanol by nonspecific esterases in the gastrointestinal tract. Etilevodopa hydrochloride is used for the treatment of Parkinson disease (PD). Levodopa is the direct precursor of dopamine and is a suitable proagent as it facilitates CNS penetration and delivers dopamine .

HY-W012264

3-O-Methyldopa monohydrate 1 Publications Verification 3-Methoxy-L-tyrosine monohydrate; 3-O-Methyl-L-DOPA monohydrate	COMT	Neurological Disease
3-O-Methyldopa monohydrate (3-Methoxy-L-tyrosine monohydrate) is a significant metabolite of L-DOPA produced through the action of catechol O-methyltransferase (COMT). Unlike its precursor, 3-O-Methyldopa does not serve as a substrate or inhibitor of L-amino acid decarboxylase activity. Additionally, the inhibition of COMT can amplify the anti-Parkinson effects of L-DOPA.

HY-113468AS1

3-O-Methyldopa-d3 hydrate 3-Methoxy-L-tyrosine-d₃ hydrate; 3-O-Methyl-L-DOPA-d₃ hydrate	Isotope-Labeled Compounds Dopamine Receptor Endogenous Metabolite	Neurological Disease
3-O-Methyldopa-d₃ (hydrate) is the deuterium labeled 3-O-Methyldopa. 3-O-Methyldopa (3-Methoxy-L-tyrosine) is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of l-DOPA and dopamine[1].

HY-113468AS

3-O-Methyldopa-d3 3-Methoxy-L-tyrosine-d₃; 3-O-Methyl-L-DOPA-d₃	Isotope-Labeled Compounds Dopamine Receptor Endogenous Metabolite	Neurological Disease
3-O-Methyldopa-d₃ (3-Methoxy-L-tyrosine-d₃) is deuterium labeled 3-O-Methyldopa (HY-113468A). 3-O-Methyldopa is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of l-DOPA and dopamine .

HY-115860

TAS-4	Others	Neurological Disease
TAS-4 is a potent and selective mGluR4 positive allosteric modulator with significant anti-Parkinson's disease activity. TAS-4 is able to show efficacy when used alone or in combination with l-DOPA. TAS-4 is able to reverse haloperidol-induced spasticity when administered alone. TAS-4 enhances the contralateral rotation behavior induced by l-DOPA in a dose-dependent manner. TAS-4 combined with low-dose l-DOPA shows anti-Parkinson's effects similar to full-dose l-DOPA without exacerbating abnormal motor side effects .

HY-106405

Nebicapone BIA 3-202	COMT	Metabolic Disease
Nebicapone (BIA 3-202), a reversible catechol-O-methyltransferase (COMT) inhibitor, is mainly metabolized by glucuronidation. Nebicapone is mainly peripherally acting inhibitor that decreases the biotransformation of L-DOPA to 3-O-methyl-DOPA by inhibition of COMT, and it is potential for the treatment of Parkinson's disease .

HY-100705

DMNB 6-Nitroveratraldehyde	Drug Intermediate	Neurological Disease
DMNB (6-Nitroveratraldehyde), a precursor, can be used for the synthesis no-carrier-added 6-[ ¹⁸F]fluoro-L-DOPA (6-FDOPA). No-Carrier-Added (NCA) 6-[18F]fluoro-L-dopa (6-FDOPA) is being produced routinely for PET investigations of dopaminergic systems .

HY-121675

2-Bromo-LSD BOL-148; Bromolysergide	Dopamine Receptor 5-HT Receptor	Neurological Disease
2-Bromo-LSD (BOL-148; Bromolysergide) is a Dopamine Receptor antagonist that directly affects dopamine neurons in the substantia nigra neostriatum. 2-Bromo-LSD increases the hydroxylation of tyrosine in striatum and antagonizes the decrease of Apomorphine-induced DOPA accumulation. 2-Bromo-LSD also blocks the 5-HT Receptor mediated DOPA formation .

HY-W401531S

(R)-3-O-Methyldopa-d3	Dopamine Receptor Endogenous Metabolite	Neurological Disease
(R)-3-O-Methyldopa-d₃ is a deuterium labeled (R)-3-O-Methyldopa, and (R)-3-O-Methyldopa is an R-enantiomer of 3-O-Methyldopa. 3-O-Methyldopa is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of L-DOPA and dopamine[1][2].

HY-W401531S1

(R)-3-O-Methyldopa-d3 hydrochloride	Dopamine Receptor Endogenous Metabolite	Neurological Disease
(R)-3-O-Methyldopa-d₃ (hydrochloride) is a deuterium labeled (R)-3-O-Methyldopa, and (R)-3-O-Methyldopa is an R-enantiomer of 3-O-Methyldopa. 3-O-Methyldopa is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of L-DOPA and dopamine[1][2].

HY-124501

LY 165163 p-NH2-PE-TFMPP	5-HT Receptor	Neurological Disease
LY 165163 is a potent 5-HT presynaptic receptor agonist. LY 165163 significantly decreases 5-HTP accumulation and increases DOPA accumulation in the cortex and striatum .

HY-100820R

Sarizotan (Standard)	5-HT Receptor Dopamine Receptor	Neurological Disease
Sarizotan (Standard) is the analytical standard of Sarizotan. This product is intended for research and analytical applications. Sarizotan (EMD 128130) is an orally active serotonin 5-HT_1A receptor and dopamine receptor agonist. Sarizotan (EMD 128130) exhibits IC₅₀ values of 6.5 nM (rat 5-HT_1A), 0.1 nM (human 5-HT_1A), 15.1 nM (rat D₂), 17 nM (human D₂), 6.8 nM (human D₃) and 2.4 nM (human D_4.2), respectively .

HY-100820

Sarizotan 1 Publications Verification EMD 128130	5-HT Receptor Dopamine Receptor	Neurological Disease
Sarizotan (EMD 128130) is an orally active serotonin 5-HT_1A receptor and dopamine receptor agonist. Sarizotan (EMD 128130) exhibits IC₅₀ values of 6.5 nM (rat 5-HT_1A), 0.1 nM (human 5-HT_1A), 15.1 nM (rat D₂), 17 nM (human D₂), 6.8 nM (human D₃) and 2.4 nM (human D_4.2), respectively .

HY-100820B

Sarizotan dihydrochloride EMD 128130 dihydrochloride	5-HT Receptor Dopamine Receptor	Neurological Disease
Sarizotan dihydrochloride (EMD 128130) is an orally active serotonin 5-HT_1A receptor and dopamine receptor agonist. Sarizotan (EMD 128130) exhibits IC₅₀ values of 6.5 nM (rat 5-HT_1A), 0.1 nM (human 5-HT_1A), 15.1 nM (rat D₂), 17 nM (human D₂), 6.8 nM (human D₃) and 2.4 nM (human D_4.2), respectively .

HY-100820A

Sarizotan hydrochloride EMD 128130 hydrochloride	5-HT Receptor Dopamine Receptor	Neurological Disease
Sarizotan hydrochloride is an orally active serotonin 5-HT_1A receptor and dopamine receptor agonist. Sarizotan hydrochloride (EMD 128130) exhibits IC₅₀ values of 6.5 nM (rat 5-HT_1A), 0.1 nM (human 5-HT_1A), 15.1 nM (rat D₂), 17 nM (human D₂), 6.8 nM (human D₃) and 2.4 nM (human D_4.2), respectively .

HY-N1750

3-(2,4-Dihydroxyphenyl)propanoic acid	Tyrosinase Endogenous Metabolite	Others
3-(2,4-Dihydroxyphenyl)propanoic acid (DPPacid) is a potent and competitive tyrosinase inhibitor, inhibits L-Tyrosine and DL-DOPA with an IC₅₀ and a K_i of 3.02 μM and 11.5 μM, respectively .

HY-116750

6-Hydroxykaempferol	Tyrosinase	Others
6-Hydroxykaempferol, a flavonoid, is a competitive tyrosinase inhibitor with an IC₅₀ value of 124 μM. 6-Hydroxykaempferol has a K_i value of 148 μM relative to L-DOPA as a substrate and effectively inhibits the activity of the enzyme by binding to the active site of the enzyme .

HY-N10950

Vanicoside E	Dopamine Receptor	Cancer
Vanicoside E is an antioxidant and antitumor agent. Vanicoside E inhibits L-Tyrosine (HY-N0473) and *L-DOPA* (HY-N0304) with IC₅₀s of 45.23 μM and 189.96 μM, respectively .

HY-149207

Tyrosinase-IN-11	Tyrosinase	Metabolic Disease
Tyrosinase-IN-11 is a potent tyrosinase inhibitor with IC₅₀s of 50 nM and 64 nM for L-tyrosinase and L-dopa, respectively. Tyrosinase-IN-11 has significant antioxidant activity and low cytotoxicity. Tyrosinase-IN-11 has the potential for skin hyperpigmentation research .

HY-W037976

Tyrosinase-IN-22 5-Chloro-2-mercaptobenzimidazole	Reactive Oxygen Species Tyrosinase	Cancer
Tyrosinase-IN-22 (compound 4) is an inhibitor of tyrosinase substrates (L-tyrosine and L-dopa) with IC₅₀s of 60 nM and 30 nM, respectively. Tyrosinase-IN-22 also shows potent antioxidant and anti-melanogenic properties, thus can be used for relevant researches .

HY-14561A

Idazoxan hydrochloride RX 781094 hydrochloride	Adrenergic Receptor Imidazoline Receptor	Neurological Disease Endocrinology
Idazoxan hydrochloride (RX 781094 hydrochloride) is an α₂-adrenoceptor antagonist and is also a imidazoline receptors (IRs) antagonist competitively antagonized the centrally induced hypotensive effect of imidazoline-like agents (IMs). Idazoxan hydrochloride also improves motor symptoms in Parkinson’s disease, L-DOPA-induced dyskinesias, and experimental Parkinsonism .

HY-P1335

CTAP	Opioid Receptor	Neurological Disease
CTAP is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC₅₀ of 3.5 nM. CTAP displays over 1200-fold selectivity over δ opioid (IC₅₀=4500 nM) and somatostatin receptors. CTAP can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction .

HY-120206B

Brasofensine sulfate BMS-204756 sulfate	Monoamine Oxidase	Neurological Disease
Brasofensine (BMS-204756) sulfate is an oral active dopamine transporter antagonist and can be used for parkinson’s disease research .

HY-120206

Brasofensine BMS-204756	Monoamine Oxidase	Neurological Disease
Brasofensine (BMS-204756) is an oral active dopamine transporter antagonist and can be used for parkinson’s disease research .

HY-120206A

Brasofensine maleate BMS-204756 maleate	Monoamine Oxidase	Neurological Disease
Brasofensine maleate(BMS-204756) sulfate is an oral active dopamine transporter antagonist and can be used for parkinson’s disease research .

HY-P1335A

CTAP TFA 1 Publications Verification	Opioid Receptor	Neurological Disease
CTAP TFA is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC₅₀ of 3.5 nM. CTAP TFA displays over 1200-fold selectivity over δ opioid (IC₅₀=4500 nM) and somatostatin receptors. CTAP TFA can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction .

HY-111242

SV 156	Dopamine Receptor	Neurological Disease
SV 156 is a potent and selective D2 dopamine receptor antagonist, with a K_i of 2.5 nM for hD2. SV 156 has approximately 40-fold binding selectivity for D2 dopamine receptors compared to the D3 receptor subtype. SV 156 can be used for L-DOPA (HY-N0304)-associated abnormal involuntary movements (AIMs) research .

HY-W152604

Cyclo(glycyl-L-leucyl) Cyclo(leu-gly)	Dopamine Receptor	Neurological Disease
Cyclo(glycyl-L-leucyl) (Cyclo(leu-gly)), a neuropeptide, down-regulates dopamine (DA) receptors and attenuates dopaminergic supersensitivity. Cyclo(glycyl-L-leucyl) inhibits the development of Morphine induced pain relief as well as dopamine receptor supersensitivity in rats. Cyclo(glycyl-L-leucyl) has the potential for the prevention of tardive and/or L-DOPA (HY-N0304)-induced dyskinesias .

Cat. No.	Product Name	Target	Research Area

HY-W096171

D-Dopa 3-Hydroxy-D-tyrosine	Carboxypeptidase	Neurological Disease
D-Dopa is a non-competitive, allosteric inhibitor for glutamate carboxypeptidase II (GCPII) with an IC₅₀ of 200 nM. D-Dopa exhibits good pharmacokinetic characteristics, and low blood-brain barrier permeability in mouse model .

HY-P1335A

CTAP TFA 1 Publications Verification	Opioid Receptor	Neurological Disease
CTAP TFA is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC₅₀ of 3.5 nM. CTAP TFA displays over 1200-fold selectivity over δ opioid (IC₅₀=4500 nM) and somatostatin receptors. CTAP TFA can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction .

HY-P1335

CTAP	Opioid Receptor	Neurological Disease
CTAP is a potent, highly selective, and BBB penetrant μ opioid receptor antagonist, with an IC₅₀ of 3.5 nM. CTAP displays over 1200-fold selectivity over δ opioid (IC₅₀=4500 nM) and somatostatin receptors. CTAP can be used for the study of L-DOPA-induced dyskinesia (LID) and opiate overdose or addiction .

HY-W152604

Cyclo(glycyl-L-leucyl) Cyclo(leu-gly)	Dopamine Receptor	Neurological Disease
Cyclo(glycyl-L-leucyl) (Cyclo(leu-gly)), a neuropeptide, down-regulates dopamine (DA) receptors and attenuates dopaminergic supersensitivity. Cyclo(glycyl-L-leucyl) inhibits the development of Morphine induced pain relief as well as dopamine receptor supersensitivity in rats. Cyclo(glycyl-L-leucyl) has the potential for the prevention of tardive and/or L-DOPA (HY-N0304)-induced dyskinesias .

Species:	Human (2) Mouse (1)
Tag:	His (2) Tag Free (1) Strep (1)
Source:	Sf9 insect cells (1) E. coli (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P74204

	DDC Protein, Mouse (sf9, His) Aromatic-L-amino-acid decarboxylase; AADC; DOPA decarboxylase; DDC	Mouse	Sf9 insect cells
	The DDC protein plays a key role in neurotransmitter synthesis as it catalyzes the decarboxylation of L-3,4-dihydroxyphenylalanine (DOPA) to produce dopamine and L-5-hydroxytryptophan to produce serotonin. These enzymatic reactions represent key steps in neurotransmitter biosynthesis and are essential for the normal functioning of the central nervous system. DDC Protein, Mouse (sf9, His) is the recombinant mouse-derived DDC protein, expressed by Sf9 insect cells , with C-His labeled tag. The total length of DDC Protein, Mouse (sf9, His) is 480 a.a., with molecular weight of ~55 kDa.

HY-P701909

	hDDC Protein, Human DDC; Aromatic-L-amino-acid decarboxylase; AADC; DOPA decarboxylase; DDC	Human	E. coli
	hDDC protein plays a central role in neurotransmitter synthesis by catalyzing the decarboxylation of L-3,4-dihydroxyphenylalanine (DOPA) to produce dopamine and L-5-hydroxytryptophan to produce serotonin. hDDC Protein, Human is the recombinant human-derived hDDC protein, expressed by E. coli , with tag free. The total length of hDDC Protein, Human is 480 a.a., .

HY-P701910

	hDDC Protein, Human (His, StrepⅡ) DDC; Aromatic-L-amino-acid decarboxylase; AADC; DOPA decarboxylase; DDC	Human	E. coli
	hDDC protein plays a central role in neurotransmitter synthesis by catalyzing the decarboxylation of L-3,4-dihydroxyphenylalanine (DOPA) to produce dopamine and L-5-hydroxytryptophan to produce serotonin. hDDC Protein, Human (His, Strep) is the recombinant human-derived hDDC protein, expressed by E. coli , with N-Strep, N-6*His labeled tag. The total length of hDDC Protein, Human (His, Strep) is 480 a.a., .

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-N0304S2

*L-DOPA-13C* 1 Publications Verification
L-DOPA- ¹³C is the ¹³C labeled L-DOPA[1]. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease[2][3][4].

HY-132404S

*(rac)-3-O-Methyl DOPA-d3*
(rac)-3-O-Methyl DOPA-d₃ is the deuterium labeled (rac)-3-O-Methyl DOPA[1].

HY-132392S

*L-DOPA-2,5,6-d3*
L-DOPA-2,5,6-d₃ is the deuterium labeled L-DOPA. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain[1][2][3].

HY-N0304S

*L-DOPA-d6*
L-DOPA-d₆ is the deuterium labeled L-DOPA. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease[1][2][3].

HY-113468AS

3-O-Methyldopa-d3
3-O-Methyldopa-d₃ (3-Methoxy-L-tyrosine-d₃) is deuterium labeled 3-O-Methyldopa (HY-113468A). 3-O-Methyldopa is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of l-DOPA and dopamine .

HY-113404S

*DL-Dopa-d6*
DL-Dopa-d₆ is the deuterium labeled DL-Dopa. DL-Dopa is a beta-hydroxylated derivative of phenylalanine.

HY-113404S1

*L-Dopa-d3*
L-Dopa-d₃ is deuterated labeled DL-Dopa (HY-113404). DL-Dopa is a beta-hydroxylated derivative of phenylalanine.

HY-N0304S1

*L-DOPA-13C6*
L-DOPA- ¹³C₆ is the ¹³C-labled L-DOPA . L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .

HY-113468AS1

3-O-Methyldopa-d3 hydrate
3-O-Methyldopa-d₃ (hydrate) is the deuterium labeled 3-O-Methyldopa. 3-O-Methyldopa (3-Methoxy-L-tyrosine) is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of l-DOPA and dopamine[1].

HY-W401531S

(R)-3-O-Methyldopa-d3
(R)-3-O-Methyldopa-d₃ is a deuterium labeled (R)-3-O-Methyldopa, and (R)-3-O-Methyldopa is an R-enantiomer of 3-O-Methyldopa. 3-O-Methyldopa is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of L-DOPA and dopamine[1][2].

HY-W401531S1

(R)-3-O-Methyldopa-d3 hydrochloride
(R)-3-O-Methyldopa-d₃ (hydrochloride) is a deuterium labeled (R)-3-O-Methyldopa, and (R)-3-O-Methyldopa is an R-enantiomer of 3-O-Methyldopa. 3-O-Methyldopa is a metabolite of L-DOPA which is formed by catechol-O-methyltransferase (COMT). 3-O-Methyldopa competitively inhibits the pharmacodynamics of L-DOPA and dopamine[1][2].

HY-W700834

Harman-d3

Harman-d₃ is deuterium labeled Harmane. Harmane is a benzodiazepine receptor inhibitor (IC₅₀=7 μM), with IC₅₀ values for mACh, Opioid Receptor, MAO-A/B, and α2-adrenergic receptor of 24 μM, 2.8 μM, 0.5 μM, 5 μM, and 18 μM, respectively. Harmane also inhibits haloperidol and serotonin, with IC₅₀ values of 163 μM and 101 μM, respectively. Harmane inhibits the I1 imidazoline receptor (IC₅₀=30 nM) to reduce blood pressure and has antidepressant, anti-anxiety, anticonvulsant, and analgesic effects. Harmane inhibits dopamine biosynthesis by decreasing tyrosine hydroxylase (TH) activity and enhancing L-DOPA-induced cytotoxicity in PC12 cells. Additionally, Harmane can increase the mutagenic effect induced by 2-acetylaminofluorene (AAF) .

HY-W777360

Harman-13C2,15N

Harman- ¹³C₂, ¹⁵N is ¹³C and ¹⁵N labeled Harmane. Harmane is a benzodiazepine receptor inhibitor (IC₅₀=7 μM), with IC₅₀ values for mACh, Opioid Receptor, MAO-A/B, and α2-adrenergic receptor of 24 μM, 2.8 μM, 0.5 μM, 5 μM, and 18 μM, respectively. Harmane also inhibits haloperidol and serotonin, with IC₅₀ values of 163 μM and 101 μM, respectively. Harmane inhibits the I1 imidazoline receptor (IC₅₀=30 nM) to reduce blood pressure and has antidepressant, anti-anxiety, anticonvulsant, and analgesic effects. Harmane inhibits dopamine biosynthesis by decreasing tyrosine hydroxylase (TH) activity and enhancing L-DOPA-induced cytotoxicity in PC12 cells. Additionally, Harmane can increase the mutagenic effect induced by 2-acetylaminofluorene (AAF) .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P82683

	DOPA Decarboxylase Antibody (YA2428) AADC; Aromatic L Amino Acid Decarboxylase; DDC; DOPA decarboxylase (aromatic L-amino acid decarboxylase); DOPA decarboxylase	WB	Human, Mouse, Rat
	DOPA Decarboxylase Antibody (YA2428) is a biotin-conjugated non-conjugated IgG antibody, targeting DOPA Decarboxylase, with a predicted molecular weight of 54 kDa (observed band size: 54 kDa). DOPA Decarboxylase Antibody (YA2428) can be used for WB experiment in human, mouse, rat background.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

DOPA

Inhibitors & Agonists

Peptides

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Natural
Products